Infliximab Trough Level
Over the past two decades great improvements in therapy of chronic inflammatory diseases have been made. The rise of TNFα biologics like infliximab has been a great step forward to ameliorating disease course and keep inflammations at remission levels for prolonged periods of time. Patients with suboptimal drug concentrations have worse outcomes than those with adequate drug levels. Therapeutic drug monitoring (TDM) for infliximab has a great potential for the management of anti TNF therapy.
Studies have shown that targeting an adequate infliximab trough level can support guidance of treatment in IBD. An optimal therapeutic window for trough levels seem to be the range from 3 to 7 µg/mL of infliximab in serum.
Adapted from Casteele et al., Gastroenterology, 2015
Quantum Blue® Infliximab
The Quantum Blue® Infliximab assay measures from 0.4 to 20 µg/mL. The target concentrations for trough level interpretation lies well within the linear range of the test. Quantum Blue® Infliximab provides a quantitative result within 15 minutes of incubation time. This offers the possibility to health care providers to act immediately before infusion of the next infliximab dose. Quantum Blue® Infliximab is unique in the diagnostics market, being the only test that can provide fast, reliable TDM for infliximab and it correlates well with the standard routine ELISAs for infliximab level determinations.
Quantum Blue® Infliximab Product Information
||Quantum Blue® Infliximab
|Time to Result
||15 min (approx.)
|Limit of Detection (LoD)
|| 0.15 µg/mL
||Quantum Blue® Reader 3rd generation/Quantum Blue® Reader 2nd generation